The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? (vol 84, pg 2185, 2015)

被引：0

|

作者：

Hartung, D. M.

机构：

来源：

NEUROLOGY | 2015年 / 85卷 / 19期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：1728 / 1728

页数：1

相关论文

共 3 条

[1] THE COST OF MULTIPLE SCLEROSIS DRUGS IN THE US AND THE PHARMACEUTICAL INDUSTRY: TOO BIG TO FAIL?
Tischner, John R.
NEUROLOGY, 2015, 85 (19) : 1727 - 1727
[2] The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Hartung, Daniel M.
Bourdette, Dennis N.
Ahmed, Sharia M.
Whitham, Ruth H.
NEUROLOGY, 2015, 84 (21) : 2185 - 2192
[3] Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis (vol 72, pg 1411, 2015)
Bourdette, D.
Hartung, D.
JAMA NEUROLOGY, 2015, 72 (12) : 1537 - 1537